Infliximab reduces activated myeloid dendritic cells, different macrophage subsets and CXCR3-positive cells in granuloma annulare.

Bürgler, Christina; Vinay, Keshavamurthy; Häfliger, Stefanie; Klötgen, Hans-Wilhelm; Yawalkar, Nikhil (2019). Infliximab reduces activated myeloid dendritic cells, different macrophage subsets and CXCR3-positive cells in granuloma annulare. Journal of dermatology, 46(9), pp. 808-811. Wiley 10.1111/1346-8138.14981

[img] Text
B-rgler_et_al-2019-The_Journal_of_Dermatology.pdf - Published Version
Restricted to registered users only
Available under License Publisher holds Copyright.

Download (1MB) | Request a copy

Disseminated granuloma annulare (GA) is a rare granulomatous dermatitis of unknown etiology. Treatment is often challenging and lack of a uniformly effective treatment, adds to the disease morbidity. Tumor necrosis factor (TNF)-α is an important cytokine in granuloma formation and previous reports have shown improvement of disseminated GA with anti-TNF-α therapy. Nevertheless, the underlying mechanism of actions of TNF-α inhibitors in GA remains unclear. Our aim was to evaluate alterations in the inflammatory infiltrate in a patient who experienced complete clearance of GA after treatment with infliximab. A skin biopsy was obtained before and 24 weeks after treatment with infliximab 5 mg/kg at weeks 0, 2, 6, 14 and 24. Immunohistochemical stains were performed in pre- and post-treatment biopsy specimens using CD1a, CD4, CD8, CD11c, CD32, CD68, CD69, CD163, CD183 and human leukocyte antigen (HLA)-DR to characterize alterations of the infiltrates. Parallel with clinical improvement, we observed a marked decrease in myeloid (CD11c) dendritic cells, different macrophage subsets (CD68, CD32, CD163) and T cells. In addition, a marked reduction of activation markers (HLA-DR, CD69) and CD183+ (CXCR3) cells was observed in post-treatment biopsy specimens. In conclusion, the clinical improvement of disseminated GA by infliximab is paralleled by inhibition of activated myeloid dendritic cells, different macrophage subsets and type 1 T cells.

Item Type:

Journal Article (Further Contribution)

Division/Institute:

04 Faculty of Medicine > Department of Dermatology, Urology, Rheumatology, Nephrology, Osteoporosis (DURN) > Clinic of Dermatology

UniBE Contributor:

Bürgler, Christina; Häfliger, Stefanie and Yawalkar, Nikhil

Subjects:

600 Technology > 610 Medicine & health

ISSN:

0385-2407

Publisher:

Wiley

Language:

English

Submitter:

Sandra Nyffenegger

Date Deposited:

27 Dec 2019 15:11

Last Modified:

27 Dec 2019 15:11

Publisher DOI:

10.1111/1346-8138.14981

PubMed ID:

31290564

Uncontrolled Keywords:

T cells dendritic cells granuloma annulare infliximab macrophages

BORIS DOI:

10.7892/boris.136743

URI:

https://boris.unibe.ch/id/eprint/136743

Actions (login required)

Edit item Edit item
Provide Feedback